Exporting Cannabis to the UK from Canada in 2026: What Licensed Producers Need to Know

The United Kingdom regulates cannabis imports through two parallel legal frameworks that apply simultaneously. The first is the Misuse of Drugs Act 1971, which classifies cannabis as a Class B controlled substance. The second is the Human Medicines Regulations 2012, which governs cannabis-based products for medicinal use (CBPMs) and determines how they may be supplied to patients.

For Canadian LPs, the practical consequence is that nearly all dried cannabis flower exported to the UK enters as an unlicensed CBPM, classified as a "special." Under MHRA Guidance Note 14, a "special" is a product specially manufactured or imported for the treatment of an individual patient after being ordered by a prescriber. Only three cannabis-derived medicines currently hold full MHRA marketing authorisation in the UK: Sativex, Epidyolex, and Nabilone. Canadian dried flower falls outside these and is therefore imported as an unlicensed product.

This classification has two immediate implications for Canadian suppliers:

• GMP certificate required. The MHRA requires that the manufacturing and assembly site hold a valid GMP certificate from a recognised authority. Health Canada's GMP framework is accepted, but the MHRA will verify it during the importer's licence inspection process.
• Third-country import path. Because Canada is not an EEA member state, UK importers must hold a Manufacturer's (Specials) Licence, not a Wholesale Distribution Authorisation, to import Canadian product. This distinction matters because it affects which UK counterpart can legally receive your shipment.

Post-Brexit, the UK is no longer covered by EMA approval pathways. The MHRA operates independently, meaning EU-GMP certification does not automatically satisfy UK requirements. Health Canada GMP certification, however, does provide an acceptable compliance baseline under MHRA inspection criteria. Canadian LPs should communicate this clearly in their supply documentation.

Schedule 2 status and its documentation implications

Cannabis-based medicinal products for prescription use are classified as Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Schedule 2 status imposes the most demanding documentation and security requirements in the UK controlled substances framework. Every shipment from Canada must be accompanied by a corresponding import authority. This is a permit issued to the UK importer by the Home Office, specifically authorising the controlled substance by name, quantity, and source country.

Canadian LPs do not apply for the UK import authority. That obligation sits with the UK importer. The LP's role is to ensure the export permit issued by Health Canada is aligned with the quantities and product specifications named in the UK Home Office authority, and that both documents travel with the shipment.

The Canadian side of the Canada-to-UK compliance framework is managed through Health Canada's Cannabis Act export permit process. This process is the same one used for Germany and Australia exports, but several documentation details must be calibrated specifically to UK requirements.

Health Canada export permit

A Canadian LP must hold a valid export permit issued by Health Canada for each shipment. The permit application requires the LP to name the receiving country, the importer of record, the product type and quantity, and the applicable import authority number from the UK Home Office. Export permits are typically shipment-specific. Blanket permits are not issued under the Cannabis Act for Schedule 2 equivalents.

A Standard Cultivation Licence alone is not sufficient. The licence must include the right to sell cannabis to an export importer. If this authorisation is not already included, the LP must apply to Health Canada for a licence amendment before submitting any export permit application.

Certificate of Analysis requirements for UK importers

UK-facing COA packages differ from those submitted to German or Australian partners in a few material ways. UK importers operating under a Manufacturer's (Specials) Licence are responsible for releasing the product into supply. Their release process requires a batch-specific COA that covers, at minimum:

• Total THC and CBD potency (measured post-decarboxylation)
• Residual solvents (if any processing occurred)
• Pesticide and heavy metal screening panels
• Microbial limits (total aerobic microbial count, total yeast and mould, absence of specified pathogens)
• Moisture content and water activity
• Foreign matter absence declaration

The COA must be produced by a laboratory accredited to ISO/IEC 17025. UK importers routinely request a copy of the lab's accreditation certificate alongside the COA. Supplying both documents as a standard package with every shipment shortens the importer's internal release review process.

Phytosanitary and CFIA requirements

Dried cannabis flower exported from Canada requires a phytosanitary certificate issued by the Canadian Food Inspection Agency (CFIA). UK border authorities will expect this documentation alongside the Health Canada export permit and the MHRA-linked importer paperwork. Missing or misdated phytosanitary certificates are among the most common causes of shipment delays at UK customs, particularly for Canadian LPs on their first or second export.

Packaging and labelling

The Cannabis Act and Cannabis Regulations set packaging standards for exported product. For the UK market specifically, importer partners routinely request that the Canadian LP's packaging clearly identifies the product as a medicinal cannabis product, not a consumer product. Batch numbers, LP licence numbers, and net weight in grams must be machine-readable and aligned with what appears in the Health Canada export permit and the UK import documentation. Any discrepancy between these numbers creates a compliance flag at the point of UK customs inspection.

The UK importer's licence stack is more complex than the equivalent in Germany or Australia, because the MHRA and Home Office operate separate authorisation processes that run in parallel. Canadian LPs evaluating potential UK distribution partners should verify that a prospective importer holds all three of the following before entering into a supply agreement.

The Canada-to-UK importer licence checklist

A Wholesale Distribution Authorisation (WDA(H)) is sometimes confused with the Manufacturer's (Specials) Licence. The WDA(H) permits distribution within the UK but does not authorise import from non-EEA countries. A UK partner holding only a WDA(H) cannot legally import directly from a Canadian LP. Verify the specific licence type before committing to a supply agreement.

The MHRA 28-day notification requirement

Under UK regulations, the Specialist Importer must notify the MHRA at least 28 days before the intended import date. This notification must include the product name, the International Non-proprietary Name or description of constituents, the quantity being imported, the name and address of the Canadian manufacturer, and the name of the UK importer. Late or missing notifications delay customs clearance. Canadian LPs should build this 28-day window into their shipment planning timeline as a hard buffer.

What "special clinical need" means in practice

Unlicensed CBPMs imported as "specials" can only be supplied where a licensed medicinal product cannot meet the patient's special clinical needs. The determination of clinical need rests with the prescribing clinician, not the importer or the LP. For a Canadian LP, this means the UK market is fundamentally prescription-driven. Every gram that enters the supply chain connects to an individual clinical decision. This is consistent with how Germany's narcotics prescriptions work, but the UK's Misuse of Drugs Regulations add a further documentation layer at the importer level that has no direct equivalent in the German BfArM import permit process.

The following sequence consolidates the documentation obligations for both the Canadian LP and the UK importer into a single workflow. This is not a legal checklist. Canadian LPs should engage legal and regulatory counsel familiar with both the Cannabis Act and UK MHRA regulations before their first shipment. It is a practical reference for understanding where each document originates and how it travels with the product.

The five-stage Canada-to-UK export documentation flow

1. LP confirms export authorisation on its Health Canada licence. The LP's licence must already include export permissions. If not, file a licence amendment with Health Canada before proceeding. Timeline: 30 to 90 days depending on existing licence type and amendment complexity.
2. UK importer applies for and receives a per-shipment import authority from the Home Office. This document names the Canadian LP, the product, and the exact quantity authorised. The Home Office import authority number becomes a required field on the Health Canada export permit application.
3. Canadian LP submits export permit application to Health Canada. The application references the UK Home Office import authority number, the MHRA-licenced importer, and the shipment details. Health Canada export permits for Schedule 2-equivalent controlled substances require the LP to also have the applicable Single Convention on Narcotic Drugs country and product classification confirmed.
4. CFIA phytosanitary inspection and certificate issuance. The LP arranges a CFIA inspection of the batch and obtains the phytosanitary certificate. This document must align exactly with the quantities named in the Health Canada export permit.
5. UK importer files MHRA 28-day notification. The importer sends the statutory notification to the MHRA at least 28 days before the shipment date. The notification package should include the LP's COA, the COA lab's ISO/IEC 17025 accreditation certificate, and the product description.

Documents that travel with every shipment:

• Health Canada export permit (original)
• Home Office import authority (copy supplied by UK importer)
• CFIA phytosanitary certificate
• Batch Certificate of Analysis (ISO/IEC 17025 lab)
• Lab accreditation certificate
• Commercial invoice and packing list
• Cannabis Act-compliant product label documentation

Common reasons UK-bound shipments are held at customs

Based on the experience of Canadian LPs entering the UK market over 2024 and 2025, the most common reasons for customs clearance delays include:

• Quantities on the CFIA phytosanitary certificate not matching the Health Canada export permit to the gram
• MHRA 28-day notification not filed, or filed fewer than 28 days before the shipment's arrival
• UK importer's import authority not yet issued when the shipment arrives (timing mismatch)
• COA not covering all analytes required by the importer's internal release specification
• Packaging identifying the product using Canadian adult-use terminology rather than medicinal cannabis language

AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain ISO/IEC 17025-tested batch data, full batch traceability, and the refined genetics documentation that UK importers expect from a Canadian supply partner entering the medical channel. Our compliance infrastructure is built for the documentation-intensive requirements of regulated pharmaceutical markets, including the UK's dual MHRA and Home Office licence environment.

Do Canadian LPs need EU-GMP certification to export to the UK?

No. EU-GMP certification is not a requirement for Canadian exports to the UK. The UK's MHRA operates independently of the European Medicines Agency following Brexit. Health Canada GMP certification is accepted as a qualifying compliance baseline under MHRA inspection criteria for Manufacturer's (Specials) Licence holders. Canadian LPs should ensure their Health Canada GMP status is documented and can be presented to UK importers during due diligence.

Who applies for the UK import permit: the Canadian LP or the UK importer?

The UK importer applies for the per-shipment import authority from the Home Office. The Canadian LP does not make this application. However, the LP must provide the importer with the exact product name, quantity, and Canadian licence details needed to complete the Home Office application. The import authority number issued by the Home Office is then referenced in the Canadian LP's Health Canada export permit application.

How long does it take to complete the first Canada-to-UK shipment?

For an LP without existing export authorisation on its Health Canada licence, the full process from licence amendment through to product delivery can take six to nine months. This includes time for the licence amendment, Home Office import authority processing, Health Canada export permit, MHRA 28-day notification, and customs clearance. LPs with export authorisation already in place and a UK partner holding all required licences can typically move product in eight to twelve weeks from first shipment planning to delivery.

Does dried cannabis flower qualify as an unlicensed special in the UK?

Yes. Dried cannabis flower does not hold MHRA marketing authorisation and therefore qualifies for supply as an unlicensed CBPM under Guidance Note 14, provided the UK importer holds a Manufacturer's (Specials) Licence and the required Controlled Drugs licence, and the product was prescribed for a patient with a documented special clinical need. Three cannabis-derived products hold full MHRA marketing authorisation in the UK: Sativex, Epidyolex, and Nabilone. None of these are dried flower products.

Can a UK wholesaler with a WDA(H) import directly from Canada?

No. A Wholesale Distribution Authorisation (WDA(H)) authorises UK distribution of medicines but does not authorise importation from non-EEA countries. To import directly from Canada, the UK counterpart must hold a Manufacturer's (Specials) Licence. Canadian LPs should verify this distinction when evaluating UK distribution partners, as an importer holding only a WDA(H) cannot legally receive a direct shipment from Canada without an additional Manufacturer's Specials authorisation in place.

Is the UK medical cannabis market large enough to justify the compliance investment?

The market has grown significantly. Home Office data shows UK medical cannabis imports reached just over 30 tonnes in 2025, double the 2024 total, with Canada accounting for 70% to 80% of supply. Prohibition Partners projects UK imports could reach approximately 149 tonnes by 2030. The compliance investment for a first shipment is material, particularly around licence verification and documentation alignment. For LPs already exporting to Germany or Australia, the additional compliance layer for the UK is incremental rather than prohibitive, since the Health Canada export permit infrastructure and ISO/IEC 17025 testing documentation are already in place.